SCHEDULE: Vanguard Discloses 5.5% Stake in Vistagen Therapeutics

The Vanguard Group reported a 5.5% beneficial ownership stake in Vistagen Therapeutics Inc., holding 1,687,735 common shares as of September 30, 2025.

Summary

• The Vanguard Group, an investment adviser, has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Vistagen Therapeutics Inc.
• As of September 30, 2025, Vanguard beneficially owns 1,687,735 shares of Vistagen Therapeutics Inc. Common Stock.
• This ownership represents 5.5% of the class of securities.
• Vanguard holds sole dispositive power over 1,497,003 shares and shared dispositive power over 190,732 shares.
• Vanguard holds shared voting power over 179,923 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment, which is generally a positive signal of confidence in the company's long-term value, without implying any immediate operational changes or financial performance.

Positives

• The disclosure of a significant stake by a major institutional investor like The Vanguard Group can be viewed as a vote of confidence in Vistagen Therapeutics Inc.'s long-term prospects.
• Vanguard's passive investment approach, as indicated by the 13G filing, suggests a belief in the company's underlying value without seeking to influence management or control.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Vistagen Therapeutics Inc.'s operational or financial performance.

Industry Context

The filing reflects ongoing institutional investment activity within the biotechnology and pharmaceutical sectors. Large asset managers like Vanguard routinely disclose passive stakes in public companies, indicating their inclusion in various index funds or actively managed portfolios. This is a standard disclosure for significant passive ownership.

Comparison to Industry Standards

• The 5.5% stake held by Vanguard is a typical level for passive institutional investors, often reflecting inclusion in broad market or sector-specific index funds.
• Compared to other biotech companies, a 5.5% institutional holding by a major fund group is a common occurrence and generally aligns with industry benchmarks for institutional interest in publicly traded firms.

Stakeholder Impact

• Shareholders may view Vanguard's significant stake as a positive indicator of institutional confidence, potentially contributing to share price stability or upward momentum.
• The presence of a large, passive institutional investor can sometimes provide a degree of stability to the shareholder base.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a passive ownership stake by a major institutional investor. While the presence of a large, reputable investor like Vanguard can be seen as a positive signal, it does not provide new fundamental information about Vistagen Therapeutics Inc.'s operations, financial performance, or strategic direction. Therefore, a 'hold' recommendation is appropriate, acknowledging the institutional interest without suggesting a change in investment thesis based solely on this ownership disclosure.

Keywords

Vistagen Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, investment adviser